O	0	5	RAZOR
O	5	6	:
O	7	8	A
O	9	14	Phase
O	15	17	II
O	18	22	Open
O	23	33	Randomized
O	34	39	Trial
O	40	42	of
O	43	52	Screening
O	53	57	Plus
B-intervention	58	67	Goserelin
O	68	71	and
B-intervention	72	82	Raloxifene
O	83	89	Versus
O	90	99	Screening
O	100	105	Alone
O	106	108	in
O	109	122	Premenopausal
O	123	128	Women
O	129	131	at
O	132	141	Increased
O	142	146	Risk
O	147	149	of
O	150	156	Breast
O	157	163	Cancer
O	163	164	.

O	165	175	Background
O	175	176	:
O	177	184	Ovarian
O	185	196	suppression
O	197	199	in
O	200	213	premenopausal
O	214	219	women
O	220	222	is
O	223	228	known
O	229	231	to
O	232	238	reduce
O	239	245	breast
O	246	252	cancer
O	253	257	risk
O	257	258	.

O	259	263	This
O	264	269	study
O	270	275	aimed
O	276	278	to
O	279	285	assess
O	286	292	uptake
O	293	296	and
O	297	307	compliance
O	308	312	with
O	313	320	ovarian
O	321	332	suppression
O	333	338	using
O	339	342	the
O	343	354	luteinizing
O	355	362	hormone
O	363	372	releasing
O	373	380	hormone
O	381	382	(
O	382	386	LHRH
O	386	387	)
O	388	396	analogue
O	396	397	,
O	398	407	goserelin
O	407	408	,
O	409	413	with
O	414	417	add
O	417	418	-
O	418	422	back
O	423	433	raloxifene
O	433	434	,
O	435	437	as
O	438	439	a
O	440	449	potential
O	450	457	regimen
O	458	461	for
O	462	468	breast
O	469	475	cancer
O	476	486	prevention
O	486	487	.

O	488	495	Methods
O	495	496	:
B-eligibility	497	502	Women
I-eligibility	503	505	at
I-eligibility	506	507	≥
I-eligibility	507	509	30
I-eligibility	509	510	%
I-eligibility	511	519	lifetime
I-eligibility	520	524	risk
I-eligibility	525	531	breast
I-eligibility	532	538	cancer
O	539	543	were
O	544	554	approached
O	555	558	and
O	559	569	randomized
O	570	572	to
B-control	573	585	mammographic
I-control	586	595	screening
I-control	596	601	alone
I-control	602	603	(
I-control	603	604	C
I-control	604	605	-
I-control	605	612	Control
I-control	612	613	)
O	614	616	or
O	617	626	screening
O	627	629	in
O	630	638	addition
O	639	641	to
O	642	649	monthly
O	650	662	subcutaneous
O	663	673	injections
O	674	676	of
O	677	678	3
O	678	679	.
O	679	680	6
O	681	683	mg
O	684	693	goserelin
O	694	697	and
O	698	708	continuous
O	709	711	60
O	712	714	mg
O	715	725	raloxifene
O	726	731	daily
O	732	738	orally
O	739	740	(
O	740	741	T
O	741	742	-
O	742	749	Treated
O	749	750	)
O	751	754	for
O	755	756	2
O	757	762	years
O	762	763	.

O	764	767	The
O	768	775	primary
O	776	784	endpoint
O	785	788	was
B-outcome-Measure	789	796	therapy
I-outcome-Measure	797	806	adherence
O	806	807	.

O	808	817	Secondary
O	818	827	endpoints
O	828	832	were
B-outcome-Measure	833	841	toxicity
I-outcome-Measure	841	842	/
I-outcome-Measure	842	849	quality
I-outcome-Measure	850	852	of
I-outcome-Measure	853	857	life
O	857	858	,
B-outcome-Measure	859	865	change
I-outcome-Measure	866	868	in
I-outcome-Measure	869	873	bone
I-outcome-Measure	874	881	density
O	881	882	,
O	883	886	and
B-outcome-Measure	887	899	mammographic
I-outcome-Measure	900	907	density
O	907	908	.

O	909	916	Results
O	916	917	:
O	918	919	A
O	920	925	total
O	926	928	of
B-total-participants	929	931	75
O	931	932	/
O	932	935	950
O	936	937	(
O	937	938	7
O	938	939	.
O	939	940	9
O	940	941	%
O	941	942	)
O	943	948	women
O	949	959	approached
O	960	966	agreed
O	967	969	to
O	970	983	randomization
O	983	984	.

O	985	987	In
O	988	991	the
O	992	993	T
O	993	994	-
O	994	997	arm
O	997	998	,
B-iv-bin-abs	999	1001	20
O	1002	1004	of
B-intervention-participants	1005	1007	38
O	1008	1009	(
B-iv-bin-percent	1009	1011	52
I-iv-bin-percent	1011	1012	%
O	1012	1013	)
O	1014	1016	of
O	1017	1022	women
B-outcome	1023	1032	completed
I-outcome	1033	1036	the
I-outcome	1037	1038	2
I-outcome	1038	1039	-
I-outcome	1039	1043	year
I-outcome	1044	1050	period
I-outcome	1051	1053	of
I-outcome	1054	1059	study
O	1060	1068	compared
O	1069	1073	with
O	1074	1077	the
O	1078	1079	C
O	1079	1080	-
O	1080	1083	arm
O	1084	1085	(
B-cv-bin-abs	1085	1087	27
O	1087	1088	/
B-control-participants	1088	1090	37
O	1090	1091	,
B-cv-bin-percent	1092	1094	73
I-cv-bin-percent	1094	1095	.
I-cv-bin-percent	1095	1096	0
I-cv-bin-percent	1096	1097	%
O	1097	1098	)
O	1098	1099	.

B-outcome	1100	1108	Dropouts
O	1109	1113	were
O	1114	1121	related
O	1122	1124	to
O	1125	1133	toxicity
O	1134	1137	but
O	1138	1142	also
O	1143	1146	the
O	1147	1151	wish
O	1152	1154	to
O	1155	1159	have
O	1160	1171	established
O	1172	1176	risk
O	1176	1177	-
O	1177	1185	reducing
O	1186	1196	procedures
O	1197	1200	and
O	1201	1207	proven
O	1208	1223	chemoprevention
O	1223	1224	.

O	1225	1227	As
O	1228	1238	relatively
O	1239	1242	few
O	1243	1248	women
O	1249	1258	completed
O	1259	1262	the
O	1263	1268	study
O	1268	1269	,
O	1270	1274	data
O	1275	1278	are
O	1279	1286	limited
O	1286	1287	,
O	1288	1291	but
O	1292	1297	those
O	1298	1300	in
O	1301	1304	the
O	1305	1306	T
O	1306	1307	-
O	1307	1310	arm
O	1311	1319	reported
O	1320	1331	significant
O	1332	1341	increases
O	1342	1344	in
B-outcome	1345	1353	toxicity
I-outcome	1354	1357	and
I-outcome	1358	1364	sexual
I-outcome	1365	1373	problems
O	1373	1374	,
O	1375	1377	no
B-outcome	1378	1384	change
I-outcome	1385	1387	in
I-outcome	1388	1395	anxiety
O	1395	1396	,
O	1397	1400	and
O	1401	1405	less
B-outcome	1406	1412	cancer
I-outcome	1413	1418	worry
O	1418	1419	.

B-outcome	1420	1426	Lumbar
I-outcome	1427	1432	spine
I-outcome	1433	1437	bone
I-outcome	1438	1445	density
O	1446	1454	declined
O	1455	1457	by
O	1458	1459	7
O	1459	1460	.
O	1460	1461	0
O	1461	1462	%
O	1463	1466	and
O	1467	1475	visually
O	1476	1484	assessed
O	1485	1497	mammographic
O	1498	1505	density
O	1506	1508	by
O	1509	1510	4
O	1510	1511	.
O	1511	1512	7
O	1512	1513	%
O	1514	1518	over
O	1519	1522	the
O	1523	1524	2
O	1524	1525	-
O	1525	1529	year
O	1530	1539	treatment
O	1540	1546	period
O	1546	1547	.

O	1548	1559	Conclusions
O	1559	1560	:
O	1561	1567	Uptake
O	1568	1570	is
O	1571	1579	somewhat
O	1580	1585	lower
O	1586	1590	than
O	1591	1601	comparable
O	1602	1609	studies
O	1610	1614	with
O	1615	1624	tamoxifen
O	1625	1628	for
O	1629	1639	prevention
O	1640	1644	with
O	1645	1651	higher
O	1652	1659	dropout
O	1660	1665	rates
O	1665	1666	.

O	1667	1677	Raloxifene
O	1678	1681	may
O	1682	1690	preserve
O	1691	1695	bone
O	1696	1703	density
O	1703	1704	,
O	1705	1708	but
O	1709	1718	reduction
O	1719	1721	in
O	1722	1734	mammographic
O	1735	1742	density
O	1743	1751	reversed
O	1752	1757	after
O	1758	1767	treatment
O	1768	1771	was
O	1772	1781	completed
O	1781	1782	.

O	1783	1789	Impact
O	1789	1790	:
O	1791	1795	This
O	1796	1801	study
O	1802	1811	indicates
O	1812	1816	that
O	1817	1823	breast
O	1824	1830	cancer
O	1831	1835	risk
O	1836	1845	reduction
O	1846	1849	may
O	1850	1852	be
O	1853	1861	possible
O	1862	1867	using
O	1868	1872	LHRH
O	1873	1881	agonists
O	1881	1882	,
O	1883	1886	but
O	1887	1895	reducing
O	1896	1904	toxicity
O	1905	1908	and
O	1909	1919	preventing
O	1920	1924	bone
O	1925	1932	changes
O	1933	1938	would
O	1939	1943	make
O	1944	1948	this
O	1949	1950	a
O	1951	1955	more
O	1956	1966	attractive
O	1967	1973	option
O	1973	1974	.

O	1975	1981	Cancer
O	1982	1991	Epidemiol
O	1992	2002	Biomarkers
O	2003	2007	Prev
O	2007	2008	;
O	2009	2011	27
O	2011	2012	(
O	2012	2013	1
O	2013	2014	)
O	2014	2015	;
O	2016	2018	58
O	2018	2019	-
O	2019	2021	66
O	2021	2022	.

O	2023	2024	©
O	2024	2028	2017
O	2029	2033	AACR
O	2033	2034	.
